Sam Cooper

Sam Cooper has a wealth of experience in the field of biology and drug discovery. In 2017, they co-founded Phenomic AI, where they are responsible for building a platform that allows for the drugging of multi-cell systems with therapeutic antibodies. This involves complex phenotypic assays, automated microscopy, deep-learning, and antibody discovery campaigns. Sam'sinitial focus is on new and difficult to treat pathways that underpin the interaction between colorectal cancer cells, the tumour stroma, and the immune system. Prior to this, from 2014, Sam was a PhD student at The Institute of Cancer Research, U. of London, where they used machine learning to solve problems in biology and drug discovery. A major focus was creating tools and analysing the behaviour of p21 over multiple rounds of the cell-cycle in live single cells for the first time ever in collaboration with Alexis Barr, which demonstrated that DNA damage acquired during S-phase is inherited by daughter cells, and deconvoluting the dynamics of p21 degradation prior to S-phase.

Sam Cooper attended Imperial College London from 2011 to 2014, where they earned a degree in Biochemistry with a focus in Life Sciences.